"Onco360 is grateful for the opportunity to partner on another therapy with the team at SpringWorks Therapeutics and become a ...

SWTX reports mixed fourth-quarter 2024 results. Its newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.

Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively ...

The FDA has approved an oral, small molecule MEK inhibitor for adult and pediatric patients 2 years of age and older with ...

Stamford, Connecticut-based SpringWorks' Gomekli (mirdametinib) has become the first medicine approved for both adults and children with plexiform neurofibromas (PN) in patients with the genetic ...

Coming after Ogsiveo at SprongWorks is Gomekli (mirdametinib), an oral small molecule designed to inhibit MEK1 and MEK2 proteins, which has been submitted for FDA approval as a treatment for ...

SpringWorks Therapeutics (NASDAQ:SWTX) jumped 10% in premarket trading after the firm reported its Q4 results and canceled ...

The FDA approved Ospomyv and Xbryk, denosumab biosimilars that could expand access to treatment for osteoporosis, cancer-related bone loss, and other endocrine diseases. The 5 mg risdiplam tablet ...

Visit us on Facebook. Opens in a new tab or window Visit us on X. Opens in a new tab or window Visit us on Instagram. Opens in a new tab or window Visit us on LinkedIn. Opens in a new tab or ...